Video Experimental Relacionado
Updated: Jul 5, 2026
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
La diabetes tipo 1, la hiperglucemia y el corazón
Ravi Retnakaran1, Bernard Zinman
1Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.
Lancet (London, England)
|May 27, 2008
Resumen
La diabetes tipo 1 eleva significativamente el riesgo de enfermedad cardiovascular. El control del azúcar en la sangre (hiperglucemia) a través de terapia intensiva es crucial para reducir las complicaciones cardíacas en estos pacientes.
Área de la Ciencia:
- Cardiología Cardiología.
- Endocrinología Endocrinología.
- Enfermedades Metabólicas Las enfermedades metabólicas.
Sus antecedentes:
- La diabetes tipo 1 (DT1) presenta un mayor riesgo de enfermedad cardiovascular (ECV), que a menudo se pasa por alto debido a la edad del paciente.
- El corazón diabético se enfrenta a múltiples amenazas: aterosclerosis acelerada, neuropatía cardíaca autónoma y cardiomiopatía intrínseca.
Objetivo del estudio:
- Para revisar la comprensión actual del impacto de la diabetes tipo 1 en el corazón.
- Para resaltar el papel central de la hiperglucemia en la mediación del riesgo de ECV en la diabetes tipo 1.
- Hacer hincapié en los beneficios del manejo intensivo de la diabetes en los resultados cardiovasculares.
Principales métodos:
- Revisión de la literatura existente y los datos de ensayos clínicos.
- Concéntrese en los hallazgos del ensayo de control de la diabetes y complicaciones / epidemiología de las intervenciones y complicaciones de la diabetes (DCCT / EDIC).
- Análisis de la relación entre la hiperglucemia y las complicaciones cardiovasculares en el DT1.
Principales resultados:
- La hiperglucemia se confirma como un mediador significativo del riesgo cardiovascular en el DT1.
- La terapia intensiva para la diabetes demuestra que reduce los resultados de las enfermedades cardiovasculares.
- El vínculo entre la hiperglucemia y las ECV en la diabetes tipo 1 ahora se ha establecido de manera concluyente.
Conclusiones:
- La hiperglucemia juega un papel central en la conducción del riesgo cardiovascular en la diabetes tipo 1.
- El control glucémico intensivo es esencial para mitigar las complicaciones cardiovasculares en pacientes con diabetes tipo 1.
- Comprender estos mecanismos es clave para mejorar la salud cardiovascular a largo plazo en la diabetes tipo 1.
Videos de Conceptos Relacionados
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...